A single-dose combination therapy that both prevents and treats anthrax infection.
Exposure to anthrax leaves susceptible hosts at prolonged risk of infection since spores can persist in vivo for months before germinating to cause life-threatening disease. Anthrax vaccine adsorbed (AVA, the licensed US vaccine) induces immunity too slowly to protect susceptible individuals post-exposure. Antibiotics prevent the proliferation of vegetative bacilli but do not block latent spores from germinating. Thus, anthrax-exposed individuals must remain on antibiotic therapy for months to eliminate the threat posed by delayed spore germination. Unfortunately, long-term antibiotic treatment is poorly tolerated and frequently discontinued. This work explores whether administering a single dose of a long-acting antibiotic (Dalbavancin) combined with a rapidly immunogenic vaccine/adjuvant combination can provide seamless protection from anthrax with minimal patient compliance. Results show that significant protection is achieved by delivering a single dose of this therapeutic combination any time before through 3 days after anthrax exposure.
Klinman
Dennis M
DM
Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, United States. klinmand@mail.nih.gov
Tross
Debra
D
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000881:Anthrax / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D022122:Anthrax Vaccines / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018899:CpG Islands / Q000276:immunology; D007202:Indicators and Reagents; D051379:Mice; D008805:Mice, Inbred A; D017334:Teicoplanin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D022122:Anthrax Vaccines; D000900:Anti-Bacterial Agents; D007202:Indicators and Reagents; D017334:Teicoplanin; C469289:dalbavancin